AIMA
EW icon

Ables Iannone Moore & Associates’s Edwards Lifesciences EW Stock Holding History

Ables Iannone Moore & Associates’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4
Closed -$305 – 142
2023
Q4 		$305 Buy
+4
New +$278 ﹤0.01% 292

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Ables Iannone Moore & Associates's EW Position: Q1 2024 in Review

Ables Iannone Moore & Associates sold out of Edwards Lifesciences (EW) in Q1 2024, closing a stake of 4 shares — an estimated $305 sold.

Ables Iannone Moore & Associates first reported a position in EW in Q4 2023 and held it in 1 quarter. The position peaked at $305 in Q4 2023. 1,279 funds tracked by Wall St. Rank hold EW as of Q1 2024.

  • Ables Iannone Moore & Associates reported no remaining Edwards Lifesciences position as of Q1 2024 after selling out during the quarter.
  • Ables Iannone Moore & Associates sold 4 Edwards Lifesciences shares in Q1 2024, an estimated $305.
  • Ables Iannone Moore & Associates first reported a position in Edwards Lifesciences in Q4 2023 and held it in 1 quarter.
  • Ables Iannone Moore & Associates's Edwards Lifesciences position peaked at $305 in Q4 2023.
  • 1,279 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2024.

Based on Ables Iannone Moore & Associates's 13F filing for Q1 2024, filed 30 Apr 2024.